Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell–NK cell axis in murine hepatocellular carcinoma model

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 2.2K citations

Life Sciences, Immunology, Oncology +17

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Seng‐Ryong Woo, Mercedes B. Fuertes, Leticia Corrales et al. · Immunity · 2014 · 1.8K citations · Full text

Life Sciences, Immunology, Oncology +12

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Jan P. Böttcher, Eduardo Bonavita, Probir Chakravarty et al. · Cell · 2018 · 1.8K citations · Full text

Medicine, Immunology, Oncology +17